NCT07684690Not yet recruiting
AI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians
Clinical Validation of AI-assisted Antidiabetic Drug Consultation System-1
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
This study tests whether an artificial intelligence (AI) tool can help doctors choose better diabetes medicines for their patients. Type 2 diabetes is very common, but there are far more patients than diabetes specialists, so many patients are treated by doctors who are not diabetes specialists. The researchers built an AI consultation system that gives doctors real-time suggestions and predictions about diabetes medicines while they are prescribing. The doctor always makes the final decision. In this trial, patients with type 2 diabetes whose blood sugar is not well controlled will be placed by chance (randomly) into one of two groups. In one group, the doctor uses the AI system when deciding on diabetes medicines. In the other group, the doctor prescribes as usual, without the AI system. All medicines used are already approved in Taiwan and given at approved doses. The study follows each patient for 12 months, with check-ups at the start and at 3, 6, 9, and 12 months. The main goal is to compare how much the patients' long-term blood sugar level (HbA1c) improves between the two groups after one year. The researchers also look at how many patients reach their blood sugar target, how often low blood sugar happens, and whether any side effects occur. The aim is to find out whether using the AI tool leads to better blood sugar control.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 29 Jun 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07684690
What you commit to
- Study type: Interventional
- Planned participants: 400
- From 1 Jul 2026 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic steroids
Other illness
- Cognitive impairment precluding understanding of the study
- Active cancer treatment within the past 6 years
Other
- Pregnancy or breastfeeding
- Recent participation in another interventional clinical trial
Who the study is looking for
- Adults aged 18 to 80 years
- Diagnosis of type 2 diabetes for at least 6 months
- HbA1c above 8% within the past 3 months
- Currently using one or more oral antidiabetic drugs
- Able to understand and provide written informed consent
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.